Home > Boards > US OTC > Biotechs >

Clinuvel Pharmaceuticals (CLVLY)

CLVLY RSS Feed
Add CLVLY Price Alert      Hide Sticky   Hide Intro
Moderator: contrarian bull
Search This Board: 
Last Post: 10/21/2019 8:05:34 PM - Followers: 19 - Board type: Free - Posts Today: 0

Clinuvel Logo           http://www.clinuvel.com/

General Information:
Clinuvel Pharmaceuticals is the leading photoprotective pharmaceutical company. Headquartered in Melbourne, Australia with offices in Baar, Switzerland, Singapore and Los Angeles Clinuvel trades as an ADR in the US.

Our Work: Source: http://www.clinuvel.com/en/our-work
Clinuvel is developing new drugs to improve the lives of individuals with severe skin disorders. Our lead technologies, SCENESSE® (afamelanotide 16mg) and CUV9900, are from a new class of drugs, known as melanocortins, which are based on the naturally occurring hormone α-MSH.

Mission Statement: Source: http://www.clinuvel.com/en/mission-statement
Clinuvel’s Mission is to provide treatment for patients who are most severely affected by light/UV and depigmentation disorders. Clinuvel develops pharmaceutical products, which belong to the family of melanocortins, to be used as prescriptive therapies.

Head Office: Source: 
http://www.clinuvel.com/en/contact
Clinuvel Pharmaceuticals Limited,
Level 14,
190 Queen Street,
Melbourne
VIC 3000
Australia
Tel: +61 3 9660 4900
Fax: +61 3 9660 4999

COMPANY HISTORY: (Source: http://www.clinuvel.com/en/company-history)


The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE®) and developing a proprietary, controlled-release implant formulation.

Since late 2005, Clinuvel has focused on developing SCENESSE® as a dermatological drug for individuals at greatest risk from visible and ultraviolet (UV) light and as a repigmentation therapy. The company has a particular focus on diseases where no existing preventative treatment exists.

Clinuvel commenced a clinical program in 2006 which focused on the rare disease erythropoietic protoporphyria (EPP), a metabolic disorder which causes painful burning reactions under the skin after even brief exposure to sunlight. The goal of Clinuvel’s EPP program is to prove that SCENESSE® can provide patients with EPP protection from sunlight by reducing the incidence and severity of EPP reactions. The ultimate objective is to provide a better quality of life for patients. Since the start of the EPP program, the company has involved more than 250 individuals with EPP in its global clinical trials. Between 2005 and today, clinical programs have also been conducted for individuals diagnosed with a range of disorders, including polymorphous light eruption, solar urticaria and organ transplant recipients who are susceptible to an extremely high rate of skin cancers.

In late 2009, Clinuvel announced that it had expanded its pipeline to include a second drug candidate, named CUV9900. Based on the same technology as SCENESSE®, CUV9900 is still in early stage development.

2010 was a pivotal year for Clinuvel. In May 2010, SCENESSE® became the first dermatological drug listed under the Italian 648/96 law, prior to its formal approval anywhere in the world. This listing allows Italian physicians to prescribe SCENESSE® to individuals with EPP with the cost of the drug reimbursed by the Italian National Health System (Sistema Sanitario Nazionale, SSN).

Later in 2010, Clinuvel also announced that it would expand its program for SCENESSE® to investigate the drug’s ability to repigment skin in the common pigmentation disorder vitiligo. Following regulatory and ethical approvals, Clinuvel’s International SCENESSE® Pilot Repigmentation Evaluation (INSPIRE) program commenced patient recruitment in 2011. A Phase II study was completed in the USA in 2013, showing that the drug had a good safety profile in vitiligo and may assist in faster repigmentation in patients when used in combination with narrowband UVB phototherapy. A Phase IIb study of the drug in vitiligo commenced in 2014 in Singapore.

In February 2012 Clinuvel lodged its first marketing authorisation application for SCENESSE® for EPP with the European Medicines Agency. In December 2014 the European Commission approved SCENESSE® for the prevention of phototoxicity in adult EPP patients.

As of December 2014, more than 900 individuals have been administered afamelanotide in Clinuvel’s clinical trials program and through compassionate use and special access schemes. To date, the drug has maintained a good safety profile in clinical trials.

 

SCENESSE® attains historic breakthrough European Marketing Authorisation

Clinuvel's Logo

European Medicines Agency CHMP approves novel drug for erythropoietic protoporphyria patients under exceptional circumstances (ART 14 (8) OF REGULATION (EC) NO 726/2004)

EXECUTIVE SUMMARY

  • SCENESSE® attains an historic breakthrough EMA approval for adult EPP patients extremely intolerant of light and UV
    Marketing authorisation in 31 European States
    Australian listed Clinuvel (ASX: CUV) has taken SCENESSE® from discovery to commercialisation
    SCENESSE® as the first drug for which patients’ and physicians’ clinical experiences were integrated EMA’s formal decision process
    Investor telephone conference-call Wednesday 29 October: 1800 Melbourne = 0900 Zurich = 0300 New York = 1500 Singapore. Details will be released to the ASX on Tuesday October 28.

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is proud to announce that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has voted in favour of marketing authorisation (MA) of Clinuvel’s drug SCENESSE® (afamelanotide 16mg) for adult patients with erythropoietic protoporphyria (EPP).

SCENESSE® is a first-in-class drug (belonging to a new drug category). EPP is a debilitating, rare genetic disorder clinically regarded as extreme intolerance to light and UV (phototoxicity). An estimated 10,000 EPP patients are affected worldwide, 45% of whom live within Europe.

Clinuvel conducted five trials testing SCENESSE® in approximately 350 adult EPP patients across Australia, Europe and the USA. The first EPP patient received the drug in 2006. Clinuvel submitted its dossier for EMA evaluation on 6 February 2012.

In September 2014, it was announced that the EMA - for the first time in its history - was incorporating patients’ and physicians’ clinical experiences with SCENESSE® in the CHMP’s decision process.

EMA Decision

On 23 October 2014 in its plenary session the CHMP voted in favour of marketing authorisation of SCENESSE®. This decision takes into account the challenges and limitations of conducting clinical trials in rare and severe disorders and allows access to treatment for patients without alternative medcine.1 Marketing authorisation is given for distribution of SCENESSE® across 31 European states.2 The CHMP’s decision will now be sent to the European Commission for formal ratification, expected within 67 days.

Clinuvel and the EMA have agreed to a comprehensive post-authorisation pharmacovigilance plan to monitor patients’ safety long term. SCENESSE® will be distributed through academic and specialised centres.

Comment

“On behalf of the Board, I congratulate shareholders and patients, experts in the field and Clinuvel’s teams around the world,” Clinuvel’s Chair, Stan McLiesh said. “I have witnessed from our staff a decade long dedication and an enormous zeal which has come together for patients and all stakeholders in a marvellous outcome, one rarely accomplished in pharmaceutical development and which is now unique to Australia.”

“Medical innovation requires an exceptional focus with a consistent strategy, passionate team and long term trust from patients, expert physicians and regulatory authorities worldwide,” Clinuvel’s CEO, Dr Philippe Wolgen said.

“Today I am excited but mostly proud that Clinuvel overcame a number of hurdles from having identified an unmet clinical need and taken a molecule from discovery to final commercial product. I congratulate our Acting Chief Scientific Officer Dr Wright and his entire team for the extraordinary achievement.”

“This outcome greatly impacts Clinuvel, our further operations and intrinsic value. The immediate goal is to distribute the drug to European patients in the coming months, while we owe it to our American and Asia-Pacific patient community to accelerate the regulatory process for them to gain access to SCENESSE®,” Dr Wolgen said.

FDA APPROVAL PROCESS

FDA decision is expected by October 8, 2019

The FDA has recognised that afamelanotide meets an unmet clinical need and treats a severe genetic condition for patients who are life-long deprived of light. SCENESSE® was granted orphan drug designation by the FDA in 2008 for the treatment of EPP patients and Fast Track Designation (FTD) in 2016, allowing for a ‘rolling review’ of the NDA. The orphan drug designation provides R&D and review incentives for drugs which may not otherwise be commercially viable to develop, while FTD assists to ensure that innovative drugs reach the patient population earlier than would be the case during a standard review process. The ‘rolling review’ under the FTD allows the FDA to start the review of the scientific dossier only when all modules have been submitted and have passed formal validation, a two-month process after submission of the final NDA module.

CLINUVEL obtained a positive FDA answer on acceptance of the current safety data, as the FDA issued a carcinogenicity waiver in 2017.

This year CLINUVEL applied for a Priority Review which would secure a maximum review period of six months, compared to the standard ten months. It is expected that the FDA will answer the request for Priority Review at the start of the review period.

The FDA has initiated a regulatory pilot scheme to involve patients in explaining the impact of diseases on their lives. The Division for Dental and Dermatology Products hosted a scientific workshop on EPP in October 2016.

The NDA dossier is expected to be lodged in Q4 2017 or Q1 2018 which could lead to approval of Scenesse Q3 2018.
 

PIPELINE

Following the approval of Clinuvel’s lead product SCENESSE® (afamelanotide 16mg), the Company is actively pursuing an expanded pipeline of products from the melanocortin family, a class of drugs that includes afamelanotide. Two novel molecules have been announced: CUV9900 and VLRX001.

CUV9900

CUV9900 is an alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue. Initial research has shown that CUV9900 is a potent skin protectant. Clinuvel intends to launch CUV9900 in various new formulations. Formulation work has commenced and Clinuvel expects the first formulations to be available for clinical testing after the commercialisation of SCENESSE® in Europe.

VLRX001

VLRX001 is an addition to the family of melanocortin analogues which provoke increased and prolonged cellular activity. It contains a specific peptide sequence, designed to make it less susceptible to degradation than physiologic (natural) alpha-melanocyte stimulating hormone (α-MSH).

The VLRX001 development work was undertaken through Clinuvel’s majority owned Singaporean subsidiary, VALLAURIX and has leveraged the knowledge gained from long term experience with the clinical use of SCENESSE®.

Formulation work will focus on the development of VLRX001 for topical self-administration by patients. The transdermal product will initially be evaluated as adjuvant maintenance therapy in the depigmentation disorder vitiligo.

Overall, the development of VLRX001 is part of Clinuvel’s life cycle management of its portfolio of products to ensure long term use and value of its technology and assets. Clinuvel will hold all rights to the final product and indications through VALLAURIX.
 

UPDATED: NOV. 2017




 
CLVLY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#706   Mind numbing stats!! Jestiron 10/21/19 08:05:34 PM
#705   And some thoughts about Vitiligo: Prevalence is app. 50 FarmaZutical 10/17/19 02:21:52 AM
#704   I posted this on ShareCafe and thought I’d FarmaZutical 10/13/19 04:27:56 AM
#703   The price at yesterday’s close was A$45 or contrarian bull 10/09/19 02:13:04 PM
#702   Excellent, congrats everyone! Cassius Longinus 10/09/19 09:53:42 AM
#701   Showing $27.05 PPS in my TDA account already?? Jestiron 10/09/19 08:53:14 AM
#700   Wow. Just wow :-) FarmaZutical 10/08/19 11:13:51 PM
#699   Congrats all. What a journey this has been. FarmaZutical 10/08/19 04:14:05 PM
#698   YES! Congratulations All!! Jestiron 10/08/19 04:07:45 PM
#697   FDA Approved! contrarian bull 10/08/19 01:22:42 PM
#696   Trading Halt until Friday. I suppose this contrarian bull 10/08/19 12:39:02 PM
#695   Big day. GLTA. Especially all the EPP sufferers FarmaZutical 10/08/19 08:53:50 AM
#694   I will certainly be keeping my eyes on Jestiron 10/05/19 11:41:24 PM
#693   We have the potential for an epic short FarmaZutical 10/04/19 02:26:52 AM
#692   From a recently published PhD thesis: Clinuvel In some ways, FarmaZutical 10/03/19 03:44:32 AM
#691   Yes, sorry - forgot the .au It a FarmaZutical 10/01/19 01:19:25 AM
#690   For those in the US not familiar with contrarian bull 10/01/19 01:07:01 AM
#689   Welcome to the last week before PDUFA on FarmaZutical 09/30/19 03:52:25 AM
#688   could be looking at $ 240 million in revenues contrarian bull 09/17/19 11:56:54 AM
#687   If you only look at the first indication, FarmaZutical 09/09/19 12:16:09 AM
#686   If everything goes as expected, what might this contrarian bull 09/08/19 10:08:49 PM
#685   Probably a bit overvalued after the ASX200 run, FarmaZutical 09/08/19 03:34:52 PM
#684   As predicted this did hit a new high. contrarian bull 09/07/19 10:56:04 PM
#683   Time for new ATH again. I wonder if FarmaZutical 06/17/19 05:21:42 AM
#682   Just to translate the (as usual) misleading PR ghmm 06/03/19 07:01:08 AM
#681   Yes, good times. Not that I’m really surprised. FarmaZutical 05/28/19 01:26:12 PM
#680   Well that looks greeaat!! LOL Jestiron 05/28/19 12:16:16 PM
#678   Not really. A good friend of mine who FarmaZutical 03/14/19 05:12:35 PM
#677   You a Technical Analysis supporter? Resistance at Jestiron 03/14/19 04:42:22 PM
#676   $20 pps. for the first time. Good to FarmaZutical 03/13/19 12:06:40 PM
#675   New company presentation for the upcoming road show FarmaZutical 03/04/19 03:34:45 AM
#674   Holy moly!!! Jestiron 03/02/19 08:40:01 AM
#673   New analyst report from Sphene Capital: FarmaZutical 03/01/19 09:56:44 AM
#672   Almost at a $1B Market Cap. That Jestiron 02/28/19 04:38:13 PM
#671   Progressing nicely but still tremendously undervalued. 2019 will FarmaZutical 02/27/19 03:38:06 PM
#670   Fantastic!!! Saw that earlier and wondered if you Jestiron 01/10/19 08:33:09 AM
#669   PDUFA date secured with priority review: July 8th. FarmaZutical 01/10/19 04:24:47 AM
#668   I see that Xeljanz (arthritis treatment) combined with Jestiron 11/28/18 04:03:56 PM
#667   Choosing VP as the new orphan indication is FarmaZutical 09/30/18 11:45:26 PM
#666   I look forward to the day you’ll benefit FarmaZutical 09/25/18 03:02:18 PM
#665   Just outstanding!! It is truly exciting to Jestiron 09/25/18 01:06:44 PM
#664   Fair value for EPP Europe is $20-25. <$50 FarmaZutical 09/25/18 12:56:23 PM
#663   Absolutely!!! Talk about your green day. Wow! Jestiron 09/24/18 06:06:16 PM
#662   Welcome to a great Monday. If you’re new FarmaZutical 09/24/18 03:05:59 AM
#661   One if the best write ups about Clinuvel FarmaZutical 09/15/18 02:56:42 AM
#660   There are controls in place to absolutely prevent Jestiron 09/13/18 12:13:54 AM
#659   I thought Martina Adams on TV show "Botched" contrarian bull 09/10/18 03:17:00 PM
#658   Yes, very nice. Seems like folks are beginning FarmaZutical 09/10/18 02:07:33 PM
#657   Now that is impressive!! Jest Jestiron 09/10/18 12:33:08 PM
#656   The latest update from Sphene Capital with upgraded FarmaZutical 09/10/18 03:17:25 AM
PostSubject